A Novel Peptide, CK2.3, Improved Bone Formation in Ovariectomized Sprague Dawley Rats

Autor: Linda Sequeira, Liyun Wang, John Nguyen, Anja Nohe
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Bone disease
Anabolism
Osteoporosis
casein kinase 2
Rats
Sprague-Dawley
lcsh:Chemistry
0302 clinical medicine
Bone Density
Osteogenesis
Femur
lcsh:QH301-705.5
Spectroscopy
bone formation
Kidney
Lumbar Vertebrae
General Medicine
Computer Science Applications
medicine.anatomical_structure
osteoblast differentiation
embryonic structures
Ovariectomized rat
medicine.medical_specialty
animal structures
Ovariectomy
BMP2
030209 endocrinology & metabolism
Bone morphogenetic protein 2
Catalysis
Article
Pelvis
Inorganic Chemistry
03 medical and health sciences
Femoral head
In vivo
Internal medicine
medicine
Animals
Physical and Theoretical Chemistry
Molecular Biology
business.industry
Organic Chemistry
fungi
CK2.3
medicine.disease
osteoporosis
Rats
030104 developmental biology
Endocrinology
lcsh:Biology (General)
lcsh:QD1-999
business
Peptides
Zdroj: International Journal of Molecular Sciences
Volume 21
Issue 14
International Journal of Molecular Sciences, Vol 21, Iss 4874, p 4874 (2020)
ISSN: 1422-0067
DOI: 10.3390/ijms21144874
Popis: Osteoporosis is a bone disease that has no definite cure. Current treatments for osteoporosis are divided into two categories: anti-resorptive and anabolic. However, these treatments are not perfect and have considerable risks. In addition, bone quality often declines over time with these treatments. We designed a peptide, CK2.3, that has both anabolic and anti-resorptive effects on bone. We reported that CK2.3 induced osteoblastic mineralization, promoted bone formation, and suppressed osteoclastogenesis in vivo. The effect of CK2.3 to rescue an osteoporosis phenotype model has never been shown. In this study, we demonstrated the effect of CK2.3 in ovariectomized rats, a standard model of osteoporosis. We systemically injected CK2.3 at 2.3 µ
g/kg each day for five consecutive days. Micro-computed tomography indicated that CK2.3 increased bone mineral density, (bone volume/tissue volume) BV/TV and (trabecular number) TbN, and decreased (trabecular space) TbSp in the femoral head. Similarly, single photon absorptiometry showed that treatment with CK2.3 increased bone mineral density in the lumbar spine and the pelvis. Additionally, we observed increased femoral shaft stiffness with ovariectomized rats treated with CK2.3. We also detected no significant changes in the weight of organs such as the heart, lung, liver, kidney, and spleen. An advantage of CK2.3 over current treatments was that it not only promoted bone formation but also improved fracture resistance. In conclusion, we demonstrated CK2.3 as a new anabolic treatment for osteoporosis.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje